In Tuesday's The Good, the Bad and the Ugly, a big eBay investor defends PayPal's prospects, while Carl Icahn strikes again. And can eBay still grow by itself?» Read More
CNBC's Phil LeBeau and Chuck Stevens, CFO of General Motors, dissect the automaker's quarterly numbers. Stevens weighs in on how the recall scandal impacted the company's bottom line. Our recall charge is overshadowing our overall results, says Stevens.
I think this is going to be the corporate story of the year, says Austan Goolsbee, 32 Advisors strategic partner, discussing how the tech giant is likely to spend its cash.
CNBC's Phil LeBeau breaks down the automaker's quarterly numbers of $0.06 EPS ex-items on revenues of $37.4 billion versus estimates of $38.40 billion.
Austan Goolsbee, 32 Advisors strategic partner, discusses whether U.S. tax policy is prompting the recent spate of M&A activity in big corporations.
CNBC's Becky Quick and the "Little Squawkers," take a look at today's top business stories to watch.
Derica Rice, Eli Lilly CFO, reveals where Eli Lilly is finding areas of growth which include animal health, oncology, diabetes, and neuroscience.
The FDA is considering new rules for e-cigarettes that are similar to those that currently govern tobacco products, reports NBC's Tom Costello.
Michael Ryan, UBS, takes a look at the quality of first quarter earnings and the outlook on the S&P 500 this year. At the end of the day it's about corporate profits and earnings, says Ryan.
Dan Morgan, Synovus Trust, shares his thoughts on Apple's new products and 7-for-1 stock split.
Nicholas Heyman, William Blair, discusses General Electric's possible acquisition of French train and power plant builder Alstom for more than $13 billion.
Bill Ackman tells CNBC that his losses from betting against Herbalife have been "more than cut in half" based on the recent downturn of the company's stock.
Dunkin' Brands plans to have 1,000 stores in the Golden State, reports CNBC's Jane Wells with a look at the company's expansion plans.
CNBC's Jim Cramer shares his thoughts on the legality of Bill Ackman's deal with Valeant to acquire Allergan, and why the SEC has an "existential crisis."
Jason Subotky, Yacktman Funds, shares his thoughts on Coca-Cola's equity compensation plan. The problem with these plans are they are complicated and a lot of the details are not fully flushed out, says Subotky.
Bill Ackman also tells CNBC that Allergan's poison-pill defense doesn't make his takeover bid more difficult.
Anthony DiClemente, Nomura senior analyst, shares his upbeat outlook on the social media giant, as advertising dollars continue to shift towards digital media.
John Stephens, AT&T CFO, delves into Ma Bell's quarterly numbers and weighs in on the company's strategy to increase its wireless subscribers.
William Ackman, Pershing Square Capital Management, explains how his partnership with Valeant is structured. And J. Michael Pearson, Valeant chairman & CEO, discusses why he partnered with Ackman instead of pursing Allergan alone. Creating shareholder value is our job, says Pearson.
William Ackman, Pershing Square Capital Management, explains why he is helping Valeant buy Allergan.
J. Michael Pearson, Valeant Pharmaceuticals chairman & CEO, weighs in on news that Allergan has adopted a "poison pill" defense strategy. Also Pearson shares his thoughts on adding some of Allergan's notable cosmetic products like Botox and Restasis to its growing arsenal.
Get the best of CNBC in your inbox